Here's to a Strong 2006! - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Here's to a Strong 2006!


Pharmaceutical Technology


Pharma restructuring. Cost-cutting efforts by major pharmaceutical companies, especially Pfizer (New York, NY, http://www.pfizer.com/) and Merck (Whitehouse Station, NJ, http://www.merck.com/), were big news in 2005, and their impact will really be felt in 2006. Because the two companies account for 30% of industry revenues and spending, these cuts will have a big effect on the market, even as companies such as Novartis (Basel, Switzerland, http://www.novartis.com/), Amgen (Thousand Oaks, CA, http://www.amgen.com/), and Genentech (South San Francisco, CA, http://www.gene.com/) accelerate their R&D spending. Several discovery services companies that relied heavily on Pfizer contracts already have had to face the music (see "Pfizer drops DPI, Tripos").

Sourcing practices. Supplier consolidation is a priority among major pharmaceutical companies. These efforts have benefited major CROs such as PPD, Quintiles, and Covance because of their global capabilities and economies of scale. But, it has been at the expense of small and mid-size companies. We expect more intense competition for the "leftovers"(i.e., the spending by early-stage and mid-size pharmaceutical companies).

Low-cost competition. Indian and Chinese CROs and CMOs are gaining a bigger share of the market, and Western companies are feeling the pressure. Asian competitors have made significant inroads into the medicinal chemistry, process development, and early-stage chemical intermediates markets. Western CMOs are making a belated effort to establish their own operations in Asia. Major pharmaceutical companies and clinical CROs are rapidly moving data management and other clinical trial services into India.

Pipeline bottlenecks. Development candidates are piling up at Phase II, but only a trickle are making it into Phase III. No one is clear about why this is happening. Hypotheses include a shortage of funding for early-stage companies and more candidates being killed over cardiac safety concerns. If the bottleneck is broken, it could be a bonanza for CMOs and large CROs. If candidates continue to die in Phase II, the promise of the early-stage pipeline won't be realized.

Funding for early-stage companies. Although private venture capital funding is available for early-stage companies, the public markets have dried up as new sources of funding. Biopharma companies are more dependent than ever on Big Pharma licensing deals, which is fortunate because Big Pharma is more dependent than ever on licensing deals to bolster anemic pipelines.

Pfizer drops DPI, Tripos

Discovery Partners International (DPI, San Diego, CA, http://www.discoverypartners.com/) and Tripos Inc. (St. Louis, MO, http://www.tripos.com/), providers of discovery-related services, are some of the first CRO casualties of Pfizer's restructuring efforts. Both companies are facing major changing themselves following the decision by Pfizer not to renew four-year-old services agreements. For DPI, the Pfizer relationship generated $92 million in revenues between 2002 and 2005 and accounted for as much as half of its total revenues in recent years. Tripos received $90 million from Pfizer during the life of its agreement.

Pfizer's decision has set off a chain of restructuring activities at DPI. The company said it will close its South San Francisco facility and consolidate operations in San Diego. DPI sold its discovery systems business, and its chairman and CEO Riccardo Pigliucci resigned after what was termed "a mutual difference of opinion" over the company's strategic plans.

Tripos did not announce immediate restructuring moves but said that it was evaluating the resources it would require for its discovery research activities and expected that a "reorganization of Tripos Discovery Research may be necessary."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
24%
Attracting a skilled workforce
30%
Obtaining/maintaining adequate financing
15%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here